• Company

    Forest identifies, develops, and delivers treatments that make a meaningful difference in people's lives

  • Investors

    Forest is building on a strong track record of commercial achievement to deliver important new medicines and strengthen our therapeutic franchises

  • Partnerships

    Forest partners with biotech and pharmaceutical companies around the world to develop and bring promising new medicines to market

  • Careers

    Joining Forest is an opportunity to become part of a forward-thinking community dedicated to helping improve patients' lives through medicine

Research & Development

R&D at Forest is focused on identifying strong, medically relevant product candidates and guiding them through the complex development lifecycle, from proof-of-concept through post-marketing.

Access our Clinical Trial Registry


More news

Forest Features


Actavis Completes Forest Laboratories Acquisition

DUBLIN, July 1, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has completed the acquisition of Forest Laboratories, Inc. (NYSE: FRX) in a cash and equity transaction currently valued at approximately $28 billion. The combination creates one of the world's fastest-growing specialty pharmaceutical companies, with annual revenues of more than $15 billion anticipated for 2015.

Continue reading


Forest Laboratories to Acquire Furiex Pharmaceuticals for $1.1 Billion in Cash to Build on a Leading Position in Gastroenterology (GI)

NEW YORK & MORRISVILLE, N.C.--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) and Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following approval. The acquisition is subject to receipt of customary regulatory approvals and approval by Furiex shareholders.

Continue reading